Researchers report a “biphasic and prolonged” minipuberty in girls, and provide reference ranges for reproductive hormones during the first year of life.
Non-autosomal dominant inheritance and the presence of structural collagen defects are associated with reduced benefit of treatment with zoledronic acid in children with osteogenesis imperfecta, researchers report.
A systematic review and meta-analysis confirms a high rate of reversal of idiopathic growth hormone deficiency, albeit strongly dependent on the peak GH cutoff used.
Dutch researchers have identified key logistic failures that may lead to adolescents with endocrine disorders failing to transition successfully from paediatric to adult tertiary care.
Children with X-linked hypophosphatemia derive similar benefits from burosumab regardless of whether they start treatment before or after the age of 5 years, shows a post-hoc analysis of a randomised trial.
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
An oral growth hormone secretagogue receptor agonist produces larger GH responses than standard stimulation tests in children with growth hormone deficiency, study findings suggest.
A study of Brazilian children with isolated SHOX haploinsufficency who were followed up until adult height has demonstrated a long-term benefit of recombinant human growth hormone therapy with or without puberty modulator treatment.
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Treatment with recombinant human growth hormone results in an increased final adult height in children with molecularly confirmed Silver–Russell syndrome, as well as an improved BMI that persists after treatment cessation, say researchers.
The benefit of initiating recombinant human growth hormone before puberty in patients with Noonan syndrome occurs regardless of whether the children carry a PTPN11 mutation, suggests research published in Endocrine Connections.
Children’s weight trajectories between birth and 4 years of age are associated with their dehydroepiandrosterone sulphate levels at age 7 years, study findings show.